HomeAI · summaries
Storia in 3 fonti
Landmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and more
Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer treatment Rasonque. The drug stunned researchers and spurred excitement in April ...
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
FDA approves new pancreatic cancer drug expected to usher in new era of treatment
The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.
- ·
endpoints.news
FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy
FDA approves Revolution Medicines' daraxonrasib (Rasonque) for second-line pancreatic cancer, after it nearly doubled survival in a Phase 3 to 13.2 months vs. 6.7 months on chemo.
